Crinetics announces positive topline results from phase 2 trial of atumelnant in congenital adrenal hyperplasia (cah)

Substantial, rapid and sustained statistically significant reductions of key biomarkers achieved across doses, including up to 80% mean reduction of androstenedione

CAH Ratings Summary

CAH Quant Ranking